首页> 美国卫生研究院文献>Journal of the Renin-Angiotensin-Aldosterone System: JRAAS >L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB
【2h】

L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB

机译:L / T型钙通道阻滞剂降低了先前接受ARB治疗的慢性肾脏病患者心率变异性的非高斯性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Introduction:Increased sympathetic nerve activity has been suggested in patients with chronic kidney disease (CKD). Pathologic sympathetic activity can alter heart rate variability (HRV), and the altered HRV has prognostic importance, so that reducing sympathetic activity may be an important strategy. Novel nonlinear HRVs, including deceleration capacity (DC), have greater predictive power for mortality. We have recently proposed an increase in a non-Gaussianity index of HRV, λ25s, which indicates the probability of volcanic heart rate deviations of departure from each standard deviation level, as a marker of sympathetic cardiac overdrive. L/T-type calcium channel blocker (L/T-CCB), azelnidipine, decreases sympathetic nerve activity in experimental and clinical studies.
机译:简介:慢性肾脏病(CKD)患者建议交感神经活动增强。病理性交感神经活动可以改变心率变异性(HRV),并且改变后的HRV具有预后意义,因此减少交感神经活动可能是重要的策略。新型的非线性HRV,包括减速能力(DC),具有更高的死亡率预测能力。最近,我们提出了HRV的非高斯指数λ25s的增加,该指数表示从每个标准偏差水平偏离的火山心率偏差的概率,作为交感心脏超速的标志。在实验和临床研究中,Azelnidipine是L / T型钙通道阻滞剂(L / T-CCB),可降低交感神经活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号